Non-Alcoholic Fatty Liver Disease Clinical Trials

Find Non-Alcoholic Fatty Liver Disease Clinical Trials Near You

Siemens Biomarker Multi-modality

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to see how well Photon Counting CT (PCCT) and ultrasound test results can find fat and scarring in the liver. They will be compared to MRI test results as the reference standard. Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study. They will also get an MRI, either on the same day or a different day, whichever is preferred. Participants will get an ultrasound on the same day as the MRI. If they have not had a hematocrit blood test in the past 24 hours, they will also receive one on the day of the CT scan.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age of 18 years or older

• Has clinically indicated CT schedule including the liver (with contrast or with and without contrast)

• Patient eligible for MR imaging

• History of chronic diffuse liver disease, steatotic liver disease, and/ or liver fibrosis

• Capable of consent

Locations
United States
North Carolina
Duke University Medical Center
RECRUITING
Durham
Contact Information
Primary
Mustafa Bashir, MD
mustafa.bashir@duke.edu
919-684-7366
Time Frame
Start Date: 2026-03-27
Estimated Completion Date: 2027-05
Participants
Target number of participants: 45
Treatments
Active_comparator: Photon Counting CT (PCCT)
Participants will get a regular CT scan on the PCCT scanner, plus a few extra pictures just for the study.
Active_comparator: MRI
Participants will get an MRI, either on the same day as the PCCT scan or a different day, whichever is preferred.
Active_comparator: Ultrasound
Participants will get an ultrasound on the same day as the MRI.
Related Therapeutic Areas
Sponsors
Leads: Duke University
Collaborators: Siemens Healthineers AG

This content was sourced from clinicaltrials.gov